PEP-CMV

BIOLOGICAL3 trials

Sponsors

University of Florida, Daniel Landi, Nationwide Children's Hospital

Conditions

Diffuse Intrinsic Pontine GliomaGlioblastomaHigh Grade GliomaMalignant GliomaRecurrent Brain Tumor, ChildhoodRecurrent Medulloblastoma

Phase 1

Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens

WithdrawnNCT01854099

University of FloridaGlioblastoma

Start: 2014-01-31End: 2014-01-31Updated: 2014-01-14

PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

Active, not recruitingNCT03299309

Daniel LandiMalignant Glioma, Recurrent Brain Tumor, Childhood, Recurrent Medulloblastoma

Start: 2018-06-29End: 2027-05-01Updated: 2026-06-18

Phase 2

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

RecruitingNCT05096481

Nationwide Children's HospitalDiffuse Intrinsic Pontine Glioma, High Grade Glioma, Recurrent Medulloblastoma

Start: 2024-07-18End: 2030-06-15Target: 120Updated: 2026-08-24

Related Papers

A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.

2025-06-124 citations

CTIM-01. OUTCOMES AND IMMUNE RESPONSES AFTER PEPTIDE VACCINATION TARGETING HUMAN CYTOMEGALOVIRUS ANTIGEN PP65 IN CHILDREN AND YOUNG ADULTS WITH RECURRENT HIGH-GRADE GLIOMA AND MEDULLOBLASTOMA: RESULTS OF A PHASE 1 TRIAL

Neuro-Oncology2024-11-01

Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma.

Journal of Clinical Oncology2024-06-015 citations

EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Neuro-Oncology2021-06-013 citations

CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Neuro-Oncology2020-11-016 citations